CliffBio
small molecule

NEUPRO

ROTIGOTINE

Loss of exclusivityMarch 2032latest FDA-listed patent expiry
CompanyUCB →View the full company profile on CliffBio

Drug detail

Brand nameNEUPRO
Active ingredientROTIGOTINE
Strength3MG/24HR
Dosage formFILM, EXTENDED RELEASE
RouteTRANSDERMAL
ModalitySmall molecule
FDA approvalApril 2012
Marketing statusRX

Listed patents

PatentExpiresType
9925150March 2032product
10130589December 2030product
10350174December 2030product
8246979September 2027product

More from UCB

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

NEUPRO patent cliff — loss of exclusivity March 2032 | CliffBio